The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Detection of somatic β-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD)
Open accessAbstract
BACKGROUND: Primary pigmented nodular adrenocortical disease (PPNAD) leads to Cushing syndrome (CS) and is often associated with Carney complex (CNC). Genetic alterations of the type 1-alpha regulatory subunit of cAMP-dependent protein kinase A (PRKAR1A) and phosphodiesterase 11A4 (PDE11A) genes have been found in PPNAD. Recent studies have demonstrated that beta-catenin mutations are frequent in adrenocortical adenomas and carcinomas and that the Wnt-signalling pathway is involved in PPNAD tumorigenesis. We hypothesized that adrenocortical adenomas that form in the context of PPNAD may harbour beta-catenin mutations. METHODS: We studied 18 patients with CS secondary to PPNAD who were screened for germline PRKAR1A and PDE11A mutations. Tumor DNA was extracted from pigmented adrenocortical adenoma and nodular adrenal hyperplasia. Mutation analysis of exons 3 and 5 of beta-catenin was performed using polymerase chain reaction and direct sequencing. Sections from formalin-fixed, paraffin-embedded tumour samples were studied by immunohistochemistry with an antibody against beta-catenin. RESULTS: Nine patients were carrying germline PRKAR1A mutations and one patient had a PDE11A mutation. We found somatic beta-catenin mutations in 2 of 18 patients (11%). In both cases, the mutations occurred in relatively large adenomas that had formed in the background of PPNAD. Tumor DNA analysis revealed a heterozygous ACC-to-GCC missense mutation in codon 41 (T41A) and a TCT-to-CCT missense mutation in codon 45 (S45P) of exon 3 of the beta-catenin gene that was confirmed at the cDNA level. There were no alterations in the DNA of PPNAD-adjacent tissues and lymphocytes from the patients, indicating somatic events. Immunohistochemistry showed nuclear accumulation of beta-catenin in more than 90% of cells in adenomatous tissue whereas no nuclear immunoreactivity was detected in adjacent PPNAD nodular cells. Nuclear translocation of beta-catenin protein in the PPNAD adenoma suggests activation of the Wnt-beta-catenin pathway in PPNAD. CONCLUSIONS: We report, for the first time, beta-catenin mutations in adenomas associated with PPNAD, further implicating Wnt-beta-catenin signalling in tumorigenesis linked to bilateral adrenal hyperplasias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutational analysis of the effector of the canonical Wnt pathway, the β-catenin gene, CTNNB1, has identified activating point mutations in over 25% of both ACAs and ACCs in children and adults (149, 206–208).”
From Adrenocortical carcinoma (2014) · cites this paper as [207]
In the citing paper
“Furthermore, mutational analysis of the β-catenin gene CTNNB1 identified activating point mutations in both ACAs and ACCs (149, 206–208).”
From Adrenocortical carcinoma (2014) · cites this paper as [207]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Polakis, P. (2000) · Genes & Development · doi:10.1101/gad.14.15.1837 · Cited by 3,183
WNT and β-catenin signalling: diseases and therapies
Moon, R. T., Kohn, A. D., Ferrari, G. V. D., & Kaykas, A. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1427 · Cited by 1,763
Kirschner, L. S., Carney, J. A., Pack, S. D., Taymans, S. E., Giatzakis, C., Cho, Y. S., Cho-Chung, Y. S., & Stratakis, C. A. (2000) · Nature Genetics · doi:10.1038/79238 · Cited by 1,153
Self-citationStratakis, C. A., Kirschner, L. S., & Carney, J. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7903 · Cited by 805
Self-citationWnt signaling in the intestinal epithelium: from endoderm to cancerPreprint
Gregorieff, A., & Clevers, H. C. (2005) · Genes & Development · doi:10.1101/gad.1295405 · Cited by 692
β-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628
β-Catenin mutations in cell lines established from human colorectal cancers
Ilyas, M., Tomlinson, I. P. M., Rowan, A., Pignatelli, M. N., & Bodmer, W. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10330 · Cited by 494
Cited by
Sorted by citations
Items 101–106 of 106
Bonnet-Serrano, F. (2021) · theses.fr (ABES) · doi:10.70675/022bf2ffz5b62z4303z9460z55629099aab6
Bilateral macronodular and micronodular hyperplasia: Biochemical, radiological and genetic diagnosis
Navas-Moreno, V., Ganga, C. S. L., Tapia-Sanchiz, M. S., Castro, M. A., & Marazuela, M. (2026) · Vitamins and hormones · doi:10.1016/bs.vh.2026.02.002
Fukumoto, T., Umakoshi, H., Iwahashi, N., Ogasawara, T., Matsuda, Y., Uchida, N., Kaneko, H., Fujita, M., Kawamura, N., Yokomoto‐Umakoshi, M., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag113
Kuhn, A. W., Lerário, A. M., Charchar, H. L. S., Mariani, B. M. P., Vaduva, P., Nishi, M. Y., Ledesma, F. L., Srougi, V., Chambo, J. L., Mendonca, B. B., et al. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag137
Metadata
- Authors
- Tadjine, M., Lampron, A., Ouadi, L., Horvath, A., Stratakis, C. A., & Bourdeau, I.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- National Institutes of Health (US)
- Corresponding author
- Bourdeau, Isabelle
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2008-08-13
- Volume
- 69
- Issue
- 3
- Pages
- 367-373
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- PMC
- PMC3138207
- OpenAlex
- W2089127970
- Cited by
- 108
- References
- 27
- Citations by year
- 2026: 5 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 9 · 2015: 4 · 2014: 9 · 2013: 4 · 2012: 8
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD000642)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- Cushing's syndrome, Wnt/β-catenin signaling, adrenal adenoma, Carney complex, PRKAR1A mutation, nuclear β-catenin
- MeSH terms
- Adenoma, Adolescent, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, Adult, Child, Child, Preschool, DNA Mutational Analysis, Female, Genetic Testing, Humans, Male, Middle Aged, Mutation, Phosphoric Diester Hydrolases, Pigmentation Disorders, 3',5'-Cyclic-GMP Phosphodiesterases, beta Catenin, Cyclic AMP-Dependent Protein Kinase RIalpha Subunit, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
